Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 2;29(8):1460–1467. doi: 10.1158/1078-0432.CCR-22-3027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2023 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Pharmacodynamic Changes in Biomarkers Over Time (A); and Changes by Best Overall Response (B) in the Gastric Cancer Cohort. Serum samples were in 31 patients who had samples available at C2D1, C3D1, and C4D1; asterisks indicate results of 1-sample Wilcoxon signed-rank test results of P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), or P < 0.0001 (****). C, cycle; D, day; ICAM, intercellular adhesion molecule; PECAM, platelet and endothelial cell adhesion molecule; TEK, TEK receptor tyrosine kinase. — Pharmacodynamic changes in biomarkers over time (A) and changes by best overall response (B) in the gastric cancer cohort. Serum samples were of 31 patients who had samples available at C2D1, C3D1, and C4D1; asterisks indicate results of 1-sample Wilcoxon signed-rank test results of P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), or P < 0.0001 (****). In part A, vertical bars represent 95% CIs. C, cycle; D, day; PECAM, platelet and endothelial cell adhesion molecule.